Femasys reported improved sales and reduced net loss in Q3 2025, driven by FemBloc sales and operational efficiencies. The company secured significant financing and achieved key regulatory milestones, including FDA IDE approval for the final FemBloc pivotal trial, positioning it for potential U.S. market entry.
Sales increased 31.4% to $729,394 in Q3 2025 compared to $554,908 in Q3 2024, primarily due to FemBloc sales.
positiveNet loss decreased to $4,194,821 ($0.10 per share) in Q3 2025 from $5,408,860 ($0.24 per share) in Q3 2024.
positiveResearch and development expenses decreased by 40.0% in Q3 2025 compared to Q3 2024, due to commercialization of development products and reduced costs.
positiveSecured $12 million in secured convertible notes and accompanying warrants, with potential for up to $58 million if all warrants are exercised.
positiveAnnounced FDA IDE approval to continue enrollment in the final phase of the FINALE pivotal trial for FemBloc.
positiveReceived regulatory approval for FemBloc in the United Kingdom and New Zealand.
positiveExpanded global partnerships with Kebomed for France and Benelux regions, and Medical Electronic Systems LLC for FemSperm Analysis Kit.
positiveInventory levels increased significantly to $5,783,974 in Q3 FY2025 from $3,046,323 in Q4 FY2024, a 90% increase.
attentionThe company reported a net loss of $4,194,821 in Q3 2025 and an accumulated deficit of $141.9 million as of September 30, 2025.
negativeDespite sales growth, the company continues to operate at a loss from operations, with a loss of $3,653,768 in Q3 2025.
negativeThe company's cash and cash equivalents of $4.6 million, even with recent financing, are expected to fund operations only into September 2026, indicating a need for further funding.
attentionMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
Third quarter marked several pivotal milestones for Femasys as we advanced on multiple fronts, securing key regulatory approvals, strengthening our balance sheet through new financing, and expanding global partnerships for FemBloc, all reinforcing our commitment to delivering innovative solutions for women’s health.
Regulatory approvals of the complete FemBloc System in the U.K. and New Zealand significantly expand access to this revolutionary, non-surgical permanent birth control option across Europe and the Asia-Pacific region.
With initial commercial orders received from our distribution partners in Spain and France, we are building early momentum as we pursue additional country approvals.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.